511 related articles for article (PubMed ID: 31787359)
21. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.
Kardile RA; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Thopate SR
Eur J Med Chem; 2023 Jan; 245(Pt 1):114889. PubMed ID: 36375337
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
[TBL] [Abstract][Full Text] [Related]
23. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
24. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent small molecule PROTACs targeting mutant EGFR.
Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
[TBL] [Abstract][Full Text] [Related]
28. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
[TBL] [Abstract][Full Text] [Related]
31. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
32. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC.
Chen L; Zhang Y; Wang C; Tang Z; Meng Q; Sun H; Qi Y; Ma X; Li L; Li Y; Xu Y
Bioorg Chem; 2021 Sep; 114():105045. PubMed ID: 34161879
[TBL] [Abstract][Full Text] [Related]
37. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
38. Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation.
Jiwacharoenchai N; Saruengkhanphasit R; Niwetmarin W; Seetaha S; Choowongkomon K; Ruchirawat S; Eurtivong C
Bioorg Med Chem Lett; 2022 Feb; 58():128524. PubMed ID: 34995690
[TBL] [Abstract][Full Text] [Related]
39. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
[TBL] [Abstract][Full Text] [Related]
40. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
